Posts by tag
targeted therapy
The Ovation and the Asterisk
Five trials, five cancers, and what the ASCO 2026 plenary really promised patients ASCO 2026’s plenary delivered five real advances across five cancers, and a standing ovation that pulled a hall full of oncologists to their feet. The harder question…
Rewriting RAS: A New Targeted Option on the Horizon for Pancreatic Cancer
Metastatic pancreatic cancer remains one of the most treatment-refractory solid tumours in oncology. Despite multiple incremental refinements over the past decade, first-line therapy continues to rely on cytotoxic chemotherapy, most commonly FOLFIRINOX or gemcitabine plus nab-paclitaxel, with limited change in…
Melanoma: treatment sequence matters
Patients with metastatic melanoma who received immunotherapy before targeted therapy showed a 20% overall survival advantage at two years versus those receiving targeted therapy first, with immunotherapy after. The final results of the DREAMseq trial, published in the Journal of…